Every Form 4 that Biofrontera Inc (BFRI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BFRI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BFRI filings page.
Biofrontera Inc. CEO and Chairman Hermann Luebbert converted 62,500 restricted stock units (RSUs) into 62,500 shares of common stock on July 28, 2026. These RSUs are part of a 125,000-unit award granted on July 22, 2025, vesting in two equal yearly installments beginning July 22, 2026. After the conversion, he directly held 352,711 shares of common stock and 62,500 RSUs from this grant, with RSUs having different terms expressly excluded.
Biofrontera Inc. Chief Financial Officer Eugene Frederick Leffler converted 31,250 restricted stock units into 31,250 shares of common stock on July 28, 2026 through an exercise of derivative securities. After this settlement, he directly holds 206,250 shares of Biofrontera common stock.
Biofrontera Inc. director Kevin Daniel Weber reported receiving an employee stock option grant to acquire 20,000 shares of the company’s stock. The option carries an exercise price of $0.00 per share and represents a new award, bringing his total directly held derivative securities from this grant to 20,000 options.
According to the disclosure, the option vests in twelve equal monthly installments beginning on April 4, 2026, meaning the right to exercise will phase in over one year. The filing notes that other options with different terms are not included in this reported transaction.
Biofrontera Inc. CEO and Chairman Hermann Luebbert reported several equity awards and an option-related share conversion. On March 4, 2026, he received 125,000 restricted stock units and an employee stock option for 125,000 shares, both at a price of $0.00 per unit or option. The restricted stock units vest in two equal yearly installments beginning on March 4, 2027, and may be settled in shares, cash, or a combination within 60 days of each vesting date. The option vests in two equal installments on September 4, 2026 and March 4, 2027. On March 5, 2026, 137,500 restricted stock units were exercised or converted into 137,500 shares of common stock at $0.00 per share, bringing his directly held common stock to 290,211 shares after the transaction.
Biofrontera Inc. Chief Financial Officer Eugene Frederick Leffler reported equity compensation activity, mainly awards and a derivative conversion. On March 4, 2026, he received 62,500 restricted stock units and 62,500 employee stock options, both granted for no cash consideration.
On March 5, 2026, 87,500 restricted stock units were converted into 87,500 shares of common stock at a price of $0.00 per share, leaving him with 175,000 common shares held directly after the transaction.
Lanckriet Heikki reported acquisition or exercise transactions in this Form 4 filing.
Biofrontera Inc. director Heikki Lanckriet received a grant of employee stock options covering 20,000 shares on March 4, 2026. These options were awarded at a stated price of $0.0000 per share and represent a new direct derivative holding of 20,000 options.
The option grant vests in twelve equal monthly installments, beginning on April 4, 2026, spreading the benefit to the director over one year. The disclosure notes that options with different terms are not included in this reported amount.
Hoffman Beth J. reported acquisition or exercise transactions in this Form 4 filing.
Biofrontera Inc. director Beth J. Hoffman reported receiving an award of 20,000 employee stock options on March 4, 2026. The options were granted at a reported price of $0.0000 per share. They vest in twelve equal monthly installments beginning on April 4, 2026. After this grant, she holds 20,000 options directly.
Biofrontera Inc. reported that Chief Commercial Officer George Patrick Jones acquired new equity-based compensation. He received 50,000 restricted stock units, each representing a contingent right to one share of BFRI common stock awarded for no consideration.
He also received an option for 50,000 shares with a grant price of $0.00. The option vests in two equal installments on September 4, 2026 and March 4, 2027. The restricted stock units vest in two equal yearly installments beginning March 4, 2027, and each vested unit will be settled in shares, cash, or a combination within 60 days at the company’s discretion.
Biofrontera Inc. director John J. Borer III received an employee stock option grant on March 4, 2026. The award covers options to purchase 20,000 shares, reported at a price of $0.00 per share as a derivative security grant. According to the terms, the option vests in twelve equal monthly installments beginning on April 4, 2026, so the director earns the right to exercise portions of the option gradually over one year.
Biofrontera AG reported acquiring 3,019 shares of Series D convertible preferred stock on 09/16/2025 in a privately negotiated transaction in exchange for assets related to U.S. production and sale of certain products with an estimated market value of $3,019,000. The Series D preferred is convertible at any time at the holder's election and has no expiration date. After the transaction the reporting person beneficially owned 4,831,172 shares of common stock and 3,019 derivative securities. The reporting entity is a director and >10% owner and has an agreement allowing it to appoint one director; Dr. Heikki Lanckriet has been deputized to serve on the issuer's board.
George Patrick Jones, identified as Chief Commercial Officer and Director of Biofrontera Inc. (BFRI), was granted an employee stock option on 09/15/2025 to purchase 100,000 shares of common stock at a $1 exercise price. The option has an expiration date of 08/25/2035 and becomes exercisable in two equal vesting installments: February 25, 2026 and August 25, 2026. Following the reported transaction, Mr. Jones beneficially owns 100,000 option shares on a direct basis. The Form 4 was signed by an attorney-in-fact, Daniel Hakansson, on 09/16/2025.
Kevin D. Weber, a director of Biofrontera Inc. (BFRI), received a grant of employee stock options on 07/22/2025. The grant comprises 20,000 options with an exercise price of $1.00 per share and an expiration date listed as 07/22/2035. The form shows 20,000 common shares beneficially owned following the reported transaction and indicates ownership is held directly. The filer states the option "vests in twelve equal monthly installments beginning on August 22, 2025." The filing was signed on behalf of Mr. Weber by an attorney-in-fact on 09/16/2025. Other options with different terms are not included.
Hermann Luebbert, CEO & Chairman and director of Biofrontera Inc. (BFRI), reported equity awards and option grants during 2024–2025. The Form 4 shows a 07/22/2025 grant of 125,000 restricted stock units (RSUs) and a contemporaneous employee stock option to buy 125,000 shares at $1.00 (exercise through 07/22/2035). On 09/10/2025 a transaction coded "M" reports acquisition of 137,500 shares (via conversion or settlement of RSUs). The RSUs convert one-for-one into common stock and were received for no consideration; some RSUs vest in two equal yearly installments beginning July 22, 2026, and other RSUs granted July 12, 2024 vest beginning July 12, 2025. Vested RSUs may be settled in shares, cash, or a combination within 60 days of vesting. The reporting was signed by an attorney-in-fact on 09/16/2025.
Biofrontera Inc. reported insider transactions by Chief Financial Officer Eugene Frederick Leffler III showing equity awards and issuances of common stock-equivalent instruments. The filing discloses that Mr. Leffler received 62,500 restricted stock units and an option to purchase 62,500 shares at $1.00 on 07/22/2025, and an additional 87,500 restricted stock units reported on 09/10/2025. The restricted stock units convert one-for-one into common shares when vested.
The 62,500 RSUs granted on 07/22/2025 vest in two equal annual installments beginning July 22, 2026, with settlement (shares, cash, or combination) within 60 days of vesting at the company's discretion. The option vests in two equal annual installments beginning January 22, 2026, and expires on July 22, 2035. The 87,500 RSUs reported on 09/10/2025 were recorded via transaction code M and are listed as acquired, leaving the reporting person with 87,500 shares following that transaction.
Heikki Lanckriet, a director of Biofrontera Inc. (BFRI), was granted an employee stock option on 07/22/2025 to purchase 20,000 shares of common stock at an exercise price of $1.00 per share. The option shows an exercise/vesting reference date of 07/22/2025 and an expiration date of 07/22/2035. The filing states the option vests in twelve equal monthly installments beginning on August 22, 2025. Following the grant, the report lists 20,000 underlying shares as beneficially owned by Mr. Lanckriet on a direct basis.
Beth J. Hoffman, a director of Biofrontera Inc. (BFRI), was granted an employee stock option on 07/22/2025 to buy 20,000 shares of common stock at an exercise price of $1.00 per share. The option becomes exercisable in monthly installments beginning August 22, 2025 and vests over twelve equal monthly installments; the option expires on July 22, 2035. The Form 4 was signed by an attorney-in-fact on September 16, 2025. The filing reports the grant as a direct beneficial ownership of 20,000 underlying shares.
John J. Borer III, a director of Biofrontera Inc. (BFRI), reported a non-derivative change dated 07/22/2025. The filing shows an employee stock option transaction: 20,000 options with a $1 exercise price, exercisable on 07/22/2025 and expiring on 07/22/2035. Following the reported transaction, 20,000 shares of common stock are shown as beneficially owned directly. The option vests in twelve equal monthly installments beginning 08/22/2025. The form is signed by Daniel Hakansson as attorney-in-fact for Mr. Borer on 09/16/2025.